tiprankstipranks
Trending News
More News >

Philogen Updates on Share Buyback Program

Story Highlights
  • Philogen specializes in developing targeted anti-cancer drugs using proprietary technologies.
  • Philogen purchased 790 shares, totaling Euro 17,775.00, as part of its buyback program.
  • Looking for the best stocks to buy? Follow the recommendations of top-performing analysts.
Philogen Updates on Share Buyback Program

Confident Investing Starts Here:

Philogen SpA ( (IT:PHIL) ) has issued an announcement.

Philogen S.p.A. has announced an update on its share buyback program, revealing the purchase of 790 shares at an average price of Euro 22.50 per share, totaling Euro 17,775.00. Since the program’s inception, the company has acquired 14,742 shares, representing 0.0363% of its share capital, which may impact its market positioning and shareholder value.

The most recent analyst rating on (IT:PHIL) stock is a Buy with a EUR25.00 price target. To see the full list of analyst forecasts on Philogen SpA stock, see the IT:PHIL Stock Forecast page.

More about Philogen SpA

Philogen is an Italian-Swiss biotechnology company focused on the research and development of pharmaceutical products, particularly targeted anti-cancer drugs. The company utilizes proprietary technologies to develop ligands that selectively deliver therapeutic agents to tumor masses, aiming to treat diseases with high mortality rates. Philogen’s approach, called vascular targeting, is primarily used for cancer treatment but is also applicable to other diseases, such as chronic inflammatory conditions.

Average Trading Volume: 9,446

Technical Sentiment Signal: Buy

Current Market Cap: €658M

See more insights into PHIL stock on TipRanks’ Stock Analysis page.

Disclaimer & Disclosure

Looking for a trading platform? Check out TipRanks' Best Online Brokers , and find the ideal broker for your trades.

Report an Issue

Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App